SCHEMBL5144102

SCHEMBL5144102

NC(=O)c1ccc2c(c1)CC(N(Cc1ccccc1)C[C@H](O)COc1ccccc1)CCC2

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PRMT5 O14744 9/20 0.42
WDR77 Q9BQA1 9/20 0.42
ALDH1A1 P00352 4/20 0.40
HTT P42858 1/20 0.40
ADRB3 P13945 1/20 0.40
POLB P06746 1/20 0.39
MAPT P10636 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
DRD3 P35462 1/20 0.38
ABCB1 P08183 3/20 0.37
GAA P10253 1/20 0.37
MAPK1 P28482 1/20 0.37
TSHR P16473 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL5143749 0.99 PRMT5 (0.42) PRMT5WDR77ALDH1A1HTTADRB3
Hydrochloric Acid SCHEMBL5146451 0.89 PRMT5 (0.45) PRMT5WDR77ALDH1A1HTTADRB3
SCHEMBL7753292 0.88 PRMT5 (0.43) PRMT5WDR77ALDH1A1HTTADRB3
SCHEMBL5145499 0.87 PRMT5 (0.45) PRMT5WDR77ALDH1A1ADRB3POLB
SCHEMBL5144081 0.86 PRMT5 (0.44) PRMT5WDR77ALDH1A1ADRB3POLB
SCHEMBL5142058 0.86 PRMT5 (0.44) PRMT5WDR77ALDH1A1ADRB3POLB
SCHEMBL5143786 0.86 PRMT5 (0.46) PRMT5WDR77ALDH1A1HTTADRB3
SCHEMBL5144057 0.86 DRD2 (0.48) PRMT5WDR77ALDH1A1ADRB3POLB
SCHEMBL5146452 0.86 PRMT5 (0.48) PRMT5WDR77ALDH1A1HTTADRB3
SCHEMBL5144073 0.85 ALDH1A1 (0.48) PRMT5WDR77ALDH1A1ADRB3POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7217706-B2 Propanolamine derivatives ASTELLAS PHARMA INC. (JP) 2007-05-15 US disclosed
EP-1382333-A2 Use of beta 3 adrenergic receptor agonists in the treatment of dysuria FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-01-21 EP disclosed
US-6495546-B1 SUCH AS 1-(N-BENZYL-N-(3-METHOXY-6,7,8,9-TETRAHYDRO-5H-BENZO-CYCLOHEPTEN-6-YL)AMINO)-3-PHENOXY-2-PROPANOL; ADRENERGIC RECEPTOR AGONISTS; ANTIULCEROUS, LIPOLYTIC, ANTIURINARY INCONTINENCE AND ANTIPOLLAKIURIA ACTIVITIES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-12-17 US disclosed
US-20020120148-A1 Propanolamine derivatives FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2002-08-29 US disclosed
EP-1070046-A1 PROPANOLAMINE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-01-24 EP disclosed
WO-1999051564-A1 PROPANOLAMINE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1999-10-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020120148-A1 Propanolamine derivatives AMY2A, PNMT, PNLIP PRMT5 849/4885WDR77 2347/4885ALDH1A1 335/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.